olmesartan has been researched along with Diabetic Retinopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Fukami, K; Imaizumi, T; Inoue, H; Matsui, T; Nakamura, K; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S | 1 |
2 other study(ies) available for olmesartan and Diabetic Retinopathy
| Article | Year |
|---|---|
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Cells, Cultured; Diabetic Retinopathy; DNA Replication; Down-Regulation; Endothelial Cells; Glycation End Products, Advanced; Humans; Imidazoles; Neovascularization, Pathologic; NF-kappa B; Promoter Regions, Genetic; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Research Design; RNA, Messenger; Tetrazoles; Transfection; Vascular Endothelial Growth Factor A | 2008 |